Latest Regulatory News

Elanor Investors Group has finalised a $125 million recapitalisation with Rockworth Capital Partners, restructuring its debt and setting the stage for expansion in Asia. The move repaid existing facilities and bolstered working capital, while a Singapore acquisition awaits regulatory green light.

Insignia Financial’s $3.3 billion acquisition by CC Capital Partners has cleared its final legal hurdle, with the Federal Court approving the scheme of arrangement and share trading set to suspend imminently. Shareholders on record will receive $4.80 per share when the deal completes later this month.

Electro Optic Systems (ASX: EOS) wraps up a three-year turnaround, reporting a $459 million order backlog despite a 27% revenue drop. The company expands its counter-drone and space control portfolio with the acquisition of the UK-based Interceptor business and a pending deal for MARSS, a European command-and-control software provider.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

AuKing Mining has agreed to acquire the Tundulu Rare Earths Project in Malawi, a large and under-explored carbonatite complex with strong historical drilling results. The acquisition is supported by a $3 million capital raise to fund exploration and drilling activities.

Multistack International has formalised the sale of nearly all its assets and liabilities to Hong Kong-based Willing Y Limited, marking a decisive end to its loss-making operations. The transaction hinges on shareholder and regulatory approvals, with completion targeted for June 30, 2026.

IRIS Metals has fortified its balance sheet with a A$5.5 million placement and is progressing towards an updated lithium-rubidium resource at Beecher while executing a farm-in deal for a tungsten project in Montana, reinforcing its diversified US critical minerals strategy.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

K2 Asset Management has decided to wind down its K2 Australian Small Cap Hedge Fund Complex ETF after a strategic review found it unlikely to meet profitability targets. The closure paves the way for reallocating capital to higher-growth areas and streamlining product offerings.

Emu NL's EMUOA securities have been suspended from trading by the ASX, pending compliance with listing rules. This move affects only the EMUOA class and signals regulatory scrutiny ahead of the company's next steps.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Axel REE is accelerating its in situ recovery (ISR) mining trials at the Caladão Project in Brazil, targeting rare earth elements and gallium extraction through a low-cost, environmentally friendly method. The company is fully funded for pilot wellfield trials at the Woolrich deposit, with expansion potential at Paraíso and Tiger Creek.